Opus Genetics, Inc.

NASDAQ:IRD

Biotechnology

Healthcare
$3.92 -0.12%

-$0.01 today

Market cap
$326.13M
Beta
0.55
P/E (TTM)
-33.0
EPS (TTM)
-$0.12
52W Low $0.90High $5.81

Volume 0.75M

Average 0.81M

IRD Research & Development

Spending on developing new products, technologies, and improvements to existing offerings.

Opus Genetics, Inc.NASDAQ: IRD

Research & Development · Q1 FY2026 · quarter ended Mar 2026

Research & development growth accelerates

Q1 FY2026 research & development of $10.58M rose 33.0% year over year, ahead of the +11.2% change in trailing-twelve-month research & development. Sequentially, it rose 1.4% from the prior quarter. Over 3 fiscal years it compounded at +29.0% a year.

Context

  • Research & development amounted to 217.0% of revenue in FY2025, down 27.2 pp from a year earlier.
  • Research & development increased in 3 of the last 3 fiscal years.
  • FY2025 was the highest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly growth of +33.0% holds above the trailing-twelve-month pace of +11.2%.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterMar 2026
$10.58M+1.4% QoQ
Last fiscal yearDec 2025
$30.81M+14.8% YoY
LTMMar 2026
$33.44M+11.2% YoY
Research & Development past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter+33.0%——
1 year+14.8%——
3-year CAGR+29.0%——
5-year CAGR——
10-year CAGR——

Research & Development history

USD · from the income statement

Latest · FY2025
30.81M USD
Year-over-year change
+14.8%
4-year CAGR
+19.4%

Research & Development vs competitors

How IRD compares with its peers on the latest reported figures

  • IRD's LTM Mar 2026 research & development of $33.44M is the 7th highest of the 10 companies compared; the peer median is $38.53M.
  • Its year-over-year change of +11.2% is the 3rd highest of 10, against a peer median of -22.6%.
  • Research & development amounts to 279.0% of revenue for IRD, versus a peer median of 448.8%.
IRD Competitors Peer median
Research & Development for IRD and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALECAlector, Inc.LTM Mar 2026$114.68M -37.7%-16.4%622.7%
ABOSAcumen Pharmaceuticals, Inc.LTM Mar 2026$96.1M -9.9%+48.0%—
INOInovio Pharmaceuticals, Inc.LTM Mar 2026$51.51M -27.2%-33.9%—
SEERSeer, Inc.LTM Mar 2026$41.33M -11.2%-6.2%274.8%
AGENAgenus Inc.LTM Mar 2026$38.53M -58.1%—31.1%
MCRBSeres Therapeutics, Inc.LTM Mar 2026$37.82M -33.6%-23.5%3297.1%
IRDOpus Genetics, Inc.LTM Mar 2026$33.44M +11.2%+29.0%279.0%
CGTXCognition Therapeutics, Inc.LTM Mar 2026$32.45M -22.6%+7.0%—
HURATuHURA Biosciences, Inc.LTM Mar 2026$21.18M +82.5%+30.2%—
TILInstil Bio, Inc.LTM Mar 2026$20.04M +101.3%-58.6%—
Peer median (excluding IRD) $38.53M-22.6%-11.3%448.8%

Competitors are the stored peer set for IRD. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Revenue589K39.85M19.05M10.99M14.2M
Cost of Revenue00000
Gross Profit589K39.85M19.05M10.99M14.2M
Gross Margin100.0%100.0%100.0%100.0%100.0%
Research & Development15.17M14.36M17.65M26.85M30.81M
Selling, General & Admin8.12M7.27M11.96M18.22M21.98M
Operating Expenses23.29M21.62M29.61M73.07M52.8M
Depreciation & Amortization4K4K6K10K53K
EBITDA(56.69M)18.22M(9.97M)(57.52M)(48.07M)
EBITDA Margin-9624.3%45.7%-52.3%-523.3%-338.6%
Operating Income(22.71M)18.23M(10.56M)(62.07M)(38.6M)
Operating Margin-3854.8%45.7%-55.5%-564.7%-271.9%
Interest Income00000
Interest Expense2K9K1.33M01.47M
Other Income / Expenses(33.99M)(23K)589K4.54M(10.99M)
Income Before Tax(56.69M)18.2M(9.97M)(57.53M)(49.59M)
Pre-Tax Margin-9625.3%45.7%-52.4%-523.4%-349.3%
Income Tax Expense0315K12K00
Net Income(56.69M)17.89M(9.99M)(57.53M)(49.59M)
Net Margin-9625.3%44.9%-52.4%-523.4%-349.3%
EPS (Basic)(3.82)0.90(0.46)(2.15)(0.80)
EPS (Diluted)(3.82)0.87(0.46)(2.15)(0.80)
Weighted Avg Shares14.85M19.93M21.59M26.72M622.22M
Weighted Avg Shares (Diluted)14.85M20.6M21.59M26.72M622.22M

Opus Genetics, Inc.

NASDAQ:IRD

Intrinsic Alpha fair value

Locked

Current Price

$3.92

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.